Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr James Watson

Dr James Watson

Podcast interview

Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

View Podcast Transcript

James Watson

IDDO Associate Director

Clinical Therapeutics

I am a statistician interested in improving the treatment of infectious diseases of global health importance. My main work focuses on severe malaria, notably improving the definition of severe malaria in areas of high malaria transmission. We have estimated that a third of children diagnosed with severe malaria in high transmission settings in fact have another cause of severe illness.

I also work on other infectious diseases: I am an investigator and study statistician for PLATCOV, a platform trial characterising in vivo antiviral effects of repurposed or novel drugs for COVID-19; I am an investigator on the CHARM project which aims to develop a new methodology for the assessment of new antiparasitic drugs for the treatment of Chagas disease.

Probabilistic classification of recurrent illness in vivax

A fully Bayesian framework that classifies recurrent vivax infection as a recrudescence, relapse or reinfection using time-to-event and genetic data. This analysis showed that high-dose primaquine is very effective (3% failure).

Causal pathways in severe malaria

A directed acyclic graph that tries to dissect causal mechanisms leading to death in severe falciparum malaria. The most important part of the causal diagram is in specifying selection biases in severe malaria: "why are certain patients in the dataset and not others?"